Candida auris and Nosocomial Infection

Curr Drug Targets. 2020;21(4):365-373. doi: 10.2174/1389450120666190924155631.

Abstract

The existence of the multi-drug resistant (MDR) pathogenic fungus, Candida auris came to light in 2009. This particular organism is capable of causing nosocomial infections in immunecompromised persons. This pathogen is associated with consistent candidemia with high mortality rate and presents a serious global health threat. Whole genome sequence (WGS) investigation detected powerful phylogeographic Candida auris genotypes which are specialized to particular geological areas indicating dissemination of particular genotype among provinces. Furthermore, this organism frequently exhibits multidrug-resistance and displays an unusual sensitivity profile. Identification techniques that are commercialized to test Candida auris often show inconsistent results and this misidentification leads to treatment failure which complicates the management of candidiasis. Till date, Candida auris has been progressively recorded from several countries and therefore its preventive control measures are paramount to interrupt its transmission. In this review, we discussed prevalence, biology, drug-resistance phenomena, virulence factors and management of Candida auris infections.

Keywords: Candida auris; candidemia; emerging pathogen; multi-drug resistance; nosocomial infection..

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antifungal Agents / pharmacology
  • Candida / cytology
  • Candida / drug effects
  • Candida / genetics*
  • Candida / pathogenicity*
  • Candidiasis / drug therapy*
  • Candidiasis / epidemiology*
  • Candidiasis / microbiology
  • Candidiasis / prevention & control
  • Child
  • Child, Preschool
  • Cross Infection / drug therapy*
  • Cross Infection / epidemiology*
  • Cross Infection / microbiology
  • Cross Infection / prevention & control
  • Drug Resistance, Multiple, Fungal / genetics
  • Drug Resistance, Multiple, Fungal / physiology
  • Female
  • Global Health
  • Humans
  • Infant
  • Infant, Newborn
  • Infection Control
  • Male
  • Middle Aged
  • Prevalence
  • Risk Factors
  • Virulence Factors
  • Young Adult

Substances

  • Antifungal Agents
  • Virulence Factors